Li M. and colleagues demonstrated that glioblastoma stem-cell-like lines exhibited increased sensitivity to ribociclib and palbociclib treatment, and palbociclib treatment in combination with N, N-diethylaminobenzaldehyde (an inhibitor of the mesenchymal driver ALDH1A3) exerted a synergistic inhibitory effect on cell proliferation [78]. Here, ALDH1A3 is linked to glioblastoma.